Impact of pigment epithelium-derived factor on colorectal cancer in vitro and in vivo
Metrics: PDF 1567 views | HTML 2629 views | ?
Rhiannon L. Harries1,2, Sioned Owen1, Fiona Ruge1, Meleri Morgan2, Jun Li3, Zhangtao Zhang3, Keith G. Harding4, Jared Torkington2, Wen G. Jiang1 and Jun Cai1
1Cardiff–China Medical Research Collaborative, Cardiff University School of Medicine, Heath Park, Cardiff, UK
2University Hospital of Wales, Heath Park, Cardiff, UK
3Department of General Surgery, Beijing Key Laboratory of Cancer Invasion and Metastasis Research and National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China
4Welsh Wound Innovation Centre, Llantrisant, UK
Jun Cai, email: [email protected]
Keywords: pigment epithelial derived factor; PEDF; colorectal cancer; metastases
Received: October 14, 2017 Accepted: March 14, 2018 Published: April 10, 2018
Pigment epithelial derived factor (PEDF) is a secreted glycoprotein that is a non-inhibitory member of the serine protease inhibitor (serpin) family. PEDF exhibits multiple biological properties including neuroprotective, anti-angiogenic, and immune-modulating. Interestingly, PEDF exerts the inhibitory effects in cancers derived from certain tissues, including prostatic, ovarian, and pancreatic carcinomas. The current study aimed to elucidate its role in colorectal cancer development. PEDF expression in human colorectal cancer tissue was assessed using quantitative polymerase chain reaction (qPCR) and immunohistochemical staining (IHC). The effect of treatment with recombinant PEDF on cellular function was examined using in vitro functional assays. PEDF expression was downregulated in colorectal cancer cell tissue. Treatment with recombinant PEDF resulted in significant decreases in the rate of colorectal cancer cell migration and invasion and an increase in cellular adhesion in colorectal cancer cell lines examined. These results indicate that upregulation of PEDF expression may serve as a new strategy for further investigation of therapeutic relevance to the prevention of the metastatic spread of colorectal cancer.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.